Adlai Nortye Announces Oral Presentation for AN4035 Program Update at ENA Symposium
Adlai Nortye Group Ltd. announced that an oral presentation regarding its AN4035 program will be featured at the 38th EORTC-NCI-AACR Symposium in November 2026.
Stocks · News reference
Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M
Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year. The company reported $13.056 million in sales
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adlai Nortye Group shares are trading higher after the company announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany for the anti-EGFR antibody cetuximab.
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.
Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody
These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid
Jefferies Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $31
Jefferies analyst Maury Raycroft initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Buy rating and announces Price Target of $31.